These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 36920217)
1. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217 [TBL] [Abstract][Full Text] [Related]
2. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228 [TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models. Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240 [TBL] [Abstract][Full Text] [Related]
5. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432 [TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Xu J; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526488 [TBL] [Abstract][Full Text] [Related]
7. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656 [TBL] [Abstract][Full Text] [Related]
8. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925 [TBL] [Abstract][Full Text] [Related]
9. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C; Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355 [TBL] [Abstract][Full Text] [Related]
10. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090 [TBL] [Abstract][Full Text] [Related]
11. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Strydom N; Ernest JP; Imperial M; Solans BP; Wang Q; Tasneen R; Tyagi S; Soni H; Garcia A; Bigelow K; Gengenbacher M; Zimmerman M; Xie M; Sarathy JP; Yang TJ; Dartois V; Nuermberger EL; Savic RM Nat Commun; 2024 Aug; 15(1):7311. PubMed ID: 39181887 [TBL] [Abstract][Full Text] [Related]
12. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Bigelow KM; Tasneen R; Chang YS; Dooley KE; Nuermberger EL Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690647 [TBL] [Abstract][Full Text] [Related]
13. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287 [TBL] [Abstract][Full Text] [Related]
19. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158 [TBL] [Abstract][Full Text] [Related]
20. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND; Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]